This study is the first to propose that an evaluation of the cytokine IP10/IL-8 (S2/S0, ratio changes at 10–12 weeks after treatment) in peripheral blood can be a suitable biomarker with high specificity and sensitivity for tumor chemo-combined immunotherapy. This evidence concerns the gene CXCL10 and neoplasm.